



ISSN: 0067-2904

Impact the some Antibiotics on Gene Expression Efflux Pump of *Klebsiella pneumoniae* Isolated from Clinical Sources

Douaa Rashed Hamady, Rana Mujahid Abdullah*

Department of Biology, College of Education for Pure Science Ibn Al-Haitham, University of Baghdad, Baghdad, Iraq.

Received: 27/10/2024

Accepted: 4/ 2/2025

Published: 28/2 /2026

Abstract

One hundred thirty bacterial samples were collected from different clinical sources, including (diuresis, sputum, wounds, blood, and burns) from different hospitals in Baghdad, including Imamain Al-Kadhmain (PBUT) Medical City, Al-Karkh General Hospital, Al-Kadhimiya Children's Hospital, The burns Hospital, Ghazi Al Hariri Hospital and Baghdad Hospital. The isolates were diagnosed with phenotypic, microscopic, and biochemical tests, and molecular diagnosis was performed by detecting the *16SrRNA* gene. After the final diagnosis, 50/130 (38.4%) of *K. pneumoniae* bacteria were obtained. The results of the study showed that the highest percentage of isolation of *K. pneumoniae* bacteria was from sputum samples of patients, which amounted to 14/60 (46.67%), followed by 25/60 (41.67%) of urine, 2/5 (40%) of burns, 6/20 (30%) of wounds and 3/15 (20%) of blood. A pattern of multi-drug resistance (MDR) was found among all *K. pneumoniae* isolates at 34 (68%). The results of the statistical analysis showed highly significant differences ($p \leq 0.001$) between most of the treatments studied for gene folding in resistant isolates, and of the treatment with the antibiotic ceftazidime was recorded the highest folding of *acrAB*, gene was (4.88 ± 2.73), followed by the combination of the antibiotics ceftazidime + gentamicin together, in *mdtK* gene (4.52 ± 0.92). The other treatments recorded increased and decreased in folding, but it was not significant ($p > 0.05$).

Keywords: *Klebsiella pneumoniae*, Efflux pump genes, Antibiotics, folding.

تأثير بعض المضادات الحيوية على التعبير الجيني لبعض جينات مضخة التدفق في الكلبسيلا الرئوية المعزولة من المصادر السريرية

دعاء راشد حمادي, رنا مجاهد عبد الله*

قسم علوم الحياة، كلية التربية للعلوم الصرفة (ابن الهيثم)، جامعة بغداد، بغداد، العراق

الخلاصة

تم جمع مائة وثلاثين عينة بكتيرية من مصادر سريرية مختلفة بما في ذلك (إدرار، البلغم، الجروح، الدم، الحروق) من مستشفيات مختلفة في بغداد، بما في ذلك مدينة الإمامين الكاظمين (عليهما السلام) الطبية، ومستشفى الكرخ العام، ومستشفى الكاظمية للأطفال، ومستشفى الحروق، ومستشفى غازي الحريري ومستشفى بغداد، وتم تشخيص العزلات بالاختبارات المظهرية والمجهريّة والكيميائية الحيوية والتشخيص الجزيئي عن

*Email: dr.ranamujahid@gmail.com

طريق الكشف عن جين *16SrRNA*. وبعد التشخيص النهائي، تم الحصول على 130/50 (38.4%) من بكتيريا *Klebsiella pneumoniae*. أظهرت نتائج الدراسة أن أعلى نسبة عزل بكتيريا الكلبسيلا الرئوية كانت من عينات القشع 30/14 (46.67%) تلتها 60/25 (41.67%) من البول، 5/2 (40%) من الحروق 20/6 (30%) من الجروح و 15/3 (20%) من الدم. تم العثور على نمط من مقاومة الأدوية المتعددة بين جميع عزلات الكلبسيلا الرئوية بنسبة 34 (68%). أظهرت نتائج التحليل الإحصائي وجود فروق ذات دلالة إحصائية عالية ($p \leq 0.001$) بين معظم المعاملات المدروسة للتعبير الجيني في العزلات المقاومة، وسجلت المعاملة بالمضاد الحيوي سيفتازيديم أعلى طي للجين *acrAB* حيث بلغ (2.73 ± 4.88) ، يليه مزيج المضادين الحيويين سيفتازيديم + جنتاميسين معاً، في الجين *mdtK* حيث بلغ (0.92 ± 4.52) ، وسجلت المعاملات الأخرى زيادة ونقصان في الطي ولكن لم يكن ذا دلالة إحصائية ($p > 0.05$).

1. Introduction

The genus *Klebsiella* belongs to the intestinal family Enterobacteriaceae [1]. In 1834, Edwin Klebs discovered the genus *Klebsiella* and gave his name [2, 3].

The genus *Klebsiella pneumoniae* is characterized as a negative for Gram stains ranging in length between (0.6-6) μm and its width ranges between (0.3-1) μm , arranged individually or in pairs, or short chains [4, 5].

Colonies appear on the blood agar, gray-white, non-hemolytic, and mucous colonies. However, some studies have reported that some of them are able to produce hemolysin on blood agar and appear as dark pink mucous colonies on (EMB) [6]. These bacteria are commonly found in water, plants, soil, and mammalian mucous surfaces [7].

The prevalence of *K. pneumoniae* may be a pathogen in hospitals in Europe and the USA due to acquiring antibiotic resistance markers that give it a selective advantage in a hospital environment. It is responsible for 6-17% of urinary tract infections (UTIs), 4-15% of septicemia cases, 7-14% of pneumonia cases, 2-4% of wound infections, 4-17% of nosocomial infections in intensive care units and 3-20% of all neonatal septicemia [8, 9].

The virulence factors of *K. pneumoniae* isolates are mediated mainly by four main groups of virulence factors: capsular polysaccharide (CPS), lipopolysaccharide (LPS), fimbriae (type 1 and type 3), and siderophores. Several additional factors, such as urease production, cytotoxins, enterotoxins, hemolysin, protein-tyrosine kinase, heat-labile endotoxin, and phosphotyrosine-phosphatase protein [10]. MDR is defined as the resistance of pathogens to one or more antimicrobial agents [11]. Several health organizations, such as the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the European Centre for Disease Prevention and Control (ECDC), have warned that treating bacterial infections with multiple antibiotics has become difficult and expensive with the use of costly drugs and require long treatment systems [12]. One of the most effective mechanisms that confer multi-drug resistance bacteria is multi-drug efflux pumps, which prevent the accumulation of antibiotics inside the cell, thereby reducing their concentration to levels below toxicity [13]. Efflux pumps enhance host resistance to antimicrobial peptides in other bacteria [14], an essential component of the host's innate immune system. This mechanism likely plays a similar role in the virulence of *K. pneumoniae*, which has efflux pumps extended over the membrane to secrete toxic compounds ranging from heavy metal ions to organic chemicals, including antibiotics [15, 16]. The overall structure of these efflux pumps is highly preserved, with an inner membrane energy transfer subunit coupled via a transducer protein to an outer membrane channel subunit that enables the expulsion of toxic compounds into the environment [17]. This study aimed to detect the resistance mechanisms in *K. pneumoniae* isolates, determine the folding of bacteria that is MDR, and detect efflux pump genes in the bacteria.

2. Methods

Collection of Sample

One hundred thirty bacterial samples were collected from different clinical sources, including (diuresis, sputum, wounds, blood, and burns) from different hospitals in Baghdad, including Imamain Al-Kadhmain (PBUS) Medical City, Al-Karkh General Hospital, Al-Kadhimiya Children's Hospital, The burns Hospital, Ghazi Al Hariri Hospital and Baghdad Hospital. The isolates were diagnosed with phenotypic, microscopic, and biochemical tests, and molecular diagnosis was performed by detecting the *16SrRNA* gene.

Isolation and Identification

Cultural identification

Bacterial isolates developed in different culture media (MacConkey agar, eosin methylene blue agar, blood agar) were initially diagnosed based on their culture characteristics, including shape, structure, color, size, edges, and height of isolated bacterial colonies [18].

Microscopic identification (Gram Stain)

Part of a single colony was stained with Gram stain [18].

Biochemical tests:

Oxidase, catalase, indole, methyl red, Voges-Proskauer and citrate (IMViC), glucose fermentation, and haemolysin tests, many of these biochemical tests have been performed to diagnose *K. pneumoniae* bacteria [19].

Molecular study

DNA extraction

The ABIopure Extraction Protocol (table 1) was used to extract DNA from bacterial isolates. The process involved preparing a broth medium, inoculating *K. pneumoniae* isolates, and incubating them for 24 hours at 37°C. The bacterial suspension was then taken and placed in sterile Eppendorf tubes. Protein digestion and cytolysis were performed using 20 µg/mL proteinase K solution and 200 µL buffer BL. Absolute ethanol was added to the sample, and the mixture was transferred to a mini-column. The tubes were centrifuged for one minute at 6000, and the precipitate was replaced with a new one. Buffer BW, Buffer TW, and Buffer AE were added, and the collection tubes were then centrifuged at maximum speed to remove the remaining wash buffer.

Table 1: PCR mixture component

No	Materials	Size µl
1	Forward primer	1
2	Reverse primer	1
3	Master mix	12.5
4	DNA template	2
5	Nuclease –free water	7.5
	Total volume	24

Quantitation of DNA

A Quantus Fluorometer was used to detect the concentration of extracted DNA to detect the quality of these samples for molecular applications. This estimation was performed according to information provided by Promega QuantiFluor dsDNA System Kit from each DNA sample, 1 µl was combined with 200 µl of QuantiFluor dsDNA 1X dye. They are

mixed well and incubated in the dark at room temperature for 5 minutes, and then the concentration values are read.

Quantitative PCR

The primers used the genes *acrAB*, *TolC*, *oqxA*, *oqxB*, and *mdtk*, shown in Table 2, and each gene has its program, as shown in Table 3, to perform calculations and experiments; Real-time PCR and gene expression used KAPA SYBR® FAST qPCR Master Mix (2X) Kit as shown in Table 4, and the gene expression values of the target genes were calculated after the completion of quantum polymerase reaction cycles. The threshold cycle values were obtained for each sample of *S.aureus* bacteria.

Threshold limit values were also calculated for the *16srRNA* gene. After obtaining the threshold limit values, the variations in the threshold limit values in the target genes were calculated by subtracting the threshold limit value of the *16srRNA* gene from the target gene values for each gene to obtain the ΔC_t value. The variations values of the *16SrRNA* control samples were then subtracted from the variations values of the treated sample values to obtain a value of $\Delta\Delta C_t$ [20].

Table 2: Sequencing of primers used in gene expression.

Primer	Sequence 5' -3'	Annealing Temp. (°C)	Product Size (bp)	Reference
<i>acrAB</i> -F	ATCAGCGGCCGGATTGGTAAA	52	312	[21]
<i>acrAB</i> -R	CGGGTTCGGGAAAATAGCGCG			
<i>tolC</i> -F	ATCAGCAACCCCGATCTGCGT	52	527	[21]
<i>tolC</i> -R	CCGGTGACTTGACGCAGTCCT			
<i>oqxA</i> -F	CTCGGCGCGATGATGCT	60	392	[22]
<i>oqxA</i> -R	CCACTCTTCACGGGAGACGA			
<i>oqxB</i> -F	TTCTCCCCGGCGGGAAGTAC	60	512	[22]
<i>oqxB</i> -R	CTCGGCCATTTTGGCGCGTA			
<i>mdtk</i> -F	GCGCTTAACTTCAGCTCA	43	453	[21]
<i>mdtk</i> -R	GATGATAAATCCACACCAGAA			
<i>16S</i> -F	GCAAGTCGAGCGGTAGCACAG	58	260	[23]
<i>16S</i> -R	CAGTGTGGCTGGTCATCCTCTC			

Table 3: Optimum conditions for Real-Time PCR reaction for genes *16SrRNA*, *acrAB*, *TolC*, *oqxA*, *oqxB*, *mdtk*

No.	Phases	Temperature °C	Time	Number of Cycles
1	Activation of the enzyme RT	37	15 min	1
2	Initial Denaturation	95	5 min	
3	Denaturation	95	20 sec	
4	Annaling			40
5	<i>16SrRNA</i>	58	20 sec	
6	<i>acrAB</i>	52		
7	<i>TolC</i>	52		
8	<i>oqxB</i> · <i>oqxA</i>	60		
	<i>mdtk</i>	43		
9	Extension	72		20 sec

Table 4: Real-Time PCR reaction mixture.

Master mix component	Volume
qPCR Master Mix	5
RT mix	0.25
MgCl ₂	0.25
Forward primer	0.5
Reverse primer	0.5
Nuclease Free Water	2.5
RNA	1
Total volume	10

Determination of Sub-MIC concentration of Gentamicin and Ceftazidime antibiotics Bacterial inoculum preparation

One ml of sterile normal saline solution was transferred to a transparent polystyrene test tube with a size of 12×75 mm. Then, bacterial suspension was prepared after adjusting bacterial suspension concentration to McFarland concentration (0.5×10^8) cells/ml using a DensiCHEK Plus Meter.

Quantitative MIC

One- hundred μl of the medium was distributed to all the wells of the microtiter plate using the micropipette; two plates of the microtiter plate were used, one for the Gentamycin and the second for the Ceftazidime. Then 100 μl of Ceftazidime was placed at a concentration of 500 $\mu\text{g}/\text{ml}$ and Gentamycin (100 $\mu\text{g}/\text{ml}$) in well column No. 1 (far left of the plate), and mix the materials in the wells in the first column using a micropipette with a size of 100 μl and mix the materials by pull-up and down method 6-8 times. After that, 100 μl were pulled from the first column and added to the second column. Then, 50 μl bacterial suspension was added to each well of the plate, with column No. 12 remaining containing the medium and bacterial suspension (positive control) and the last row containing the medium and antibiotic without the bacterial suspension (negative control). Finally, the plate was incubated at a temperature of 37 °C for (18-24) hours, after which 20 μl of resazurin stain, which was prepared previously, was added to each well in the plate and incubated for an additional two hours at a temperature of 37 °C. The color change was observed and recorded, and then the MIC concentrations at which the color change occurred were taken as the minimum inhibitory concentration (MIC).

RNA Purification

RNA was extracted from bacterial isolates according to the instructions of the TRIzol™ Reagen group. RNA precipitation is done by adding 0.5 ml of isopropanol to the aqueous phase, incubating for 10 minutes, and centrifuging using a centrifuge at a speed of 12000 rpm for 10 minutes. 0.5 ml of ethanol was added to wash the RNA, then centrifuged using a centrifuge at 10,000 rpm for 5 minutes. RNA was rehydrated in 50 μl nuclease-free water and then incubated in a water bath or thermal mass at 55-60°C for 10-15 minutes.

Quantus Fluorometer was used to determine RNA concentration to detect sample quality for the final assay of 1 μl of RNA. 200 μl of diluted QuantiFluor reagent to QuantiFluor buffer was mixed and incubated for 5 minutes at room temperature in a dark place, and RNA concentration values were determined.

Calculation of RTT-PCR results

The relative levels of expression obtained by amplifying the genetic yield by the cycle threshold (Ct) value, according to Livak and Schmittgen [20], were interpreted as follows:-

$$\Delta Ct (\text{patients}) = Ct (\text{patients}) - Ct (16S rRNA)$$

$$\Delta Ct (\text{controls}) = Ct (\text{controls}) - Ct (16S rRNA)$$

$$\Delta\Delta Ct = \Delta Ct (\text{patients}) - \Delta Ct (\text{controls})$$

$$\text{Folding} = 2^{-\Delta\Delta Ct}$$

Statistical analysis

The data was tabulated in a datasheet of IBM SPSS version 25.0, which was utilized to do the statistical analysis. The mean and standard errors of continuous variables were reported, and significant differences were tested using the analysis of variance (ANOVA) test, followed by the least significant difference (LSD) test. Statistical significance was defined as a probability value ($p \leq 0.05$).

3. Result and Discussion

Isolation and detection of strains from clinical samples

One hundred thirty samples were collected from patients hospitalized in several hospitals in Baghdad, including (Imam Al-Kadhimin Hospital, Al-Karkh General Hospital, Kadhimiya Children's Hospital, Burns Hospital, Ghazi Al-Hariri Hospital and Baghdad Hospital). They included 60 samples of urine, 30 samples of sputum, 20 samples of wounds, 15 samples of blood, and 5 samples of burns, as shown in Table 5. After the isolation, the bacterial isolates were diagnosed with phenotypic, microscopic, and biochemical tests. The molecular diagnosis was done by detecting the *16SrRNA* gene, and after final diagnosis, 50 (38.4%) of *K. pneumoniae* bacteria were obtained from the total samples. The results of the study showed that the highest percentage of *K. pneumoniae* bacteria isolation was from sputum samples, which amounted to 14/30 (46.67%) of the total isolates (130), 2/60(41.67%) of urine, 2/5(40.00%) of burns, 6/20(30.00%) of wounds, 3/15(20.00%) of blood, as shown in Table (5).

Table 5: Source of isolation, number, and percentages of *K. pneumoniae* isolates.

Source of isolation	No. of <i>K. pneumoniae</i> isolates/ total bacteria isolates	Percentage
Urine	25/60	41.67%
Sputum	14/30	46.67%
Wound	6/20	30.00%
Blood	3/15	20.00%
Burns	2/5	40.00%
Total number	50/130	38.46%

The results of the study showed that the highest percentage of *K. pneumoniae* bacteria isolation was from sputum samples for patients, as it amounted to 14/30 (46.67%) of the total isolates. The results were consistent with Mohammed *et al.* [25], who found that a total of 120 samples from different clinical sources were obtained from Anbar Teaching Hospital, the highest percentage of *K. pneumoniae* isolates were obtained from sputum samples were 60 isolates (50%), followed by urine samples were 40 isolates (33.33%), 10 isolates (8.33%) of blood samples, and 10 isolates (8.33%) of wound samples.

The results differed from Razavi *et al.* [24] study; it was found that the highest infection of *K. pneumoniae* bacteria was from the urine samples, where 64 isolates (58.18%) were obtained from 110 *K. pneumoniae* samples in urine samples, 31 isolates (28.18%) of sputum samples, and 15 isolates (13.63%) of blood samples. The reason for the appearance of *K. pneumoniae* bacteria at a higher rate in sputum is because it is a typical sign of pneumonia caused by this species of bacteria [26, 27].

Diagnostic tests for isolates

Phenotypic identification

The results showed that the bacteria *K. pneumoniae* growing on MacConkey agar medium appeared to be bright pink colonies with a mucous structure, which was a characteristic of these bacteria because it was lactose fermented [28], which is non-motile, non-spore-forming, oxidase negative, containing a prominent polysaccharide capsule of wide thickness, which gives a mucous appearance to the colonies on the culture media [4, 5]. They also grow rapidly on nutrient agar and appear large, pink, round, and mucous colonies on MacConkey agar, indicating lactose fermentation and acid production. It also grows rapidly on nutrient agar media, blood agar media, and eosin methylene blue agar (EMB) [29, 30].

Microscopic identification

The results of the microscopic examination of the bacteria under light microscopy were micro-negative bacilli of Gram stains with single or double chains or in short chains, which is consistent with the results of Mahon and Lehman [31].

Biochemical identification

The results of the biochemical tests showed that all isolates were negative for the oxidase, the indole, the motility, and the methyl red tests. The isolates were positive for the urease, citrate, catalase, and Voges-Proskauer tests, and all results were consistent with those of Mohammed *et al.* [32].

Molecular diagnostics

After *K. pneumoniae* isolates were diagnosed phenotypically, microscopically and by biochemical tests, all *K. pneumoniae* isolates were subjected to molecular diagnosis using PCR technology to confirm the diagnosis using the *16S rRNA* gene because it is characterized as a stable gene and low variability for long periods in the bacterial species, the results of electrophoresis showed that all *K. pneumoniae* isolates (50 isolates) by 100% possess the *16S rRNA* gene, as shown in Figure 1, and by comparing the replication bands and the DNA ladder, the resulting bands were found to have a molecular weight of 260 base pairs.




Figure 1: Electrophoresis of the PCR product of the *16S rRNA* gene (260 base pairs) of *K. pneumoniae* isolates on agarose gel at a concentration of (0.2%) and a potential difference of 100 volts for 60 minutes. Line M (volume index) 100 – 1500 base pairs. Lines (K1-9) in Fig. (A4), (K10-18) in Fig. (B4), (K19-27) in Fig. (C4), (K28-36) in Fig. (D4), (K37-45) in Fig. (E4), (K46-50) in Fig. (F4).

Detection of multidrug-resistant isolates of *K. pneumoniae*

The results of the study showed that the pattern of multi-drug resistance (MDR) was 34 (68%) of the *K. pneumoniae* isolates studied. The result of the study agreed with the study carried out by Obaid and Hasson [33], in which they found that the percentage of antibiotic resistance among *K. pneumoniae* isolates was 50 (66.6%). Zaidan *et al.* [34] also showed in their study that 54% of *K. pneumoniae* isolates were resistant to many drugs where they were resistant to at least one antibiotic from three or more different groups of antibiotics [35]. The

appearance of MDR isolates limits the effectiveness of existing antibiotics. The risk becomes more complex when MDR-producing ESBL isolates spread worldwide, leading to a public health challenge and treatment failure [36].

Minimum Inhibitory Concentrations (MICs) of efflux pump inhibitor

Minimal inhibitory concentration (MIC) is defined as the lowest concentration of an antimicrobial agent that can inhibit the visible growth of a particular microorganism after 24-hour incubation. Clinically, antibiotic doses for specific infections are determined according to the MIC. Therefore, a reliable evaluation of MIC will provide the physician with valuable information about the choice of therapeutic strategy [37]. The minimum inhibitory concentrations MIC of Gentamycin and Ceftazidime antibiotics were determined using the microdilution method in the Mueller-Hinton broth, and the results were interpreted 24 hours after incubation at 37°C according to the Clinical Laboratory Standards Institute [38]. The result of MIC Sub was 25 µg/ml for antibiotic-resistant isolates (11, 22, 25, 33, 41) for Gentamycin, as in Figure 2. The results of Sub MIC for antibiotic-resistant isolates to Ceftazidime was 3.9 µg/ml for four bacterial isolates (22, 25, 33, 41), while for the isolate (11) was 1.9 µg/ml, as shown in Figure 3.




Figure 2: Minimum inhibitory concentrations (MICs) of Gentamycin antibiotic at concentrations (0.1-100 µg/ml) against *K. pneumoniae* isolates by Microtiter Plate test with Resazurin dye.




Figure 3: Minimum inhibitory concentrations (MICs) of the antibiotic Ceftazidime at concentrations (0.48-500 µg/ml) against *K. pneumoniae* isolates by Microtiter Plate test with Resazurin dye.

Narimisa *et al.* [39] indicated in their study of the Gentamicin and Ceftazidime antibiotics MIC against the bacteria *K. pneumoniae* ATCC 13883 using the broth microdilution method, they found MIC for two antibiotics 0.5 and 0.25 mg/ml, respectively. The studies confirmed that their results showed a decrease in bacterial cells after exposure to the sub-MIC levels of Gentamicin and Ceftazidime, indicating a greater effect of sub-MIC levels of Gentamicin and Ceftazidime on the growth of *K. pneumoniae*. Since the concentration of antibiotics in different tissues is often lower than the concentration of MIC, exposure to lethal doses of antibiotics appears necessary for the effective treatment of *K. pneumoniae* infection [40].

Gene Expression

Five isolates of *K. pneumoniae* that were multi-drug resistant were selected to study the effect of both the antibiotics Ceftazidime and Gentamicin and synergized together on the expression of the five efflux pump genes *acrAB*, *TolC*, *oqxA*, *oqxB*, and *mdtK*. Sub-MIC concentrations were selected for the tested isolates to study their effect on gene expression because these concentrations do not affect bacterial growth, and the *16SrRNA* gene was used as the housekeeping gene in the present study because its expression remains constant in the studied cells under different conditions [41]. The results of gene expression after statistical analysis (Table 6 and Figure 4) showed significant differences $p \leq 0.002$ between most of the studied treatments for gene folding in resistant isolates. The isolates treated with Ceftazidime recorded the highest gene expression in *acrAB* gene (4.88 ± 2.73) compared with control and other antibiotics treatments, followed by the isolated treated with the combination of antibiotics Ceftazidime+Gentamicin together in *mdtK* gene (4.52 ± 0.92) compared with control and other antibiotics treatments, while the other treated genes with the antibiotics recorded increased or decreased in the gene expression but it was non-significant differences ($p > 0.05$). Antibiotics of aminoglycosides and cephalosporins classes are commonly used to treat inflammatory conditions caused by *K. pneumoniae*, and the choice of antibacterial depends on the patient's health, medical history, and severity of disease [42, 43]. *K. pneumoniae* isolates show resistance to a number of major classes of antibiotics, including those of cephalosporins and aminoglycosides, leading to antibiotic failure [44]. Active efflux pumps of all kinds are widely found in the genome of *K. pneumoniae*. These pumps selectively or non-selectively pump drugs or substrates present in bacteria out of the body, resulting in a decrease in the concentration of antibacterial drugs in the body and drug resistance [45].

Through the results, it is clear that the genes for *oqxA*, *acrAB*, *tolC*, and *mdtK* efflux pumps recorded the highest folding in the isolates of resistant *K. pneumoniae* bacteria and treatment with Ceftazidime compared with control treatment, which belongs to the family of cephalosporins, followed by the combination of antibiotics Ceftazidime+Gentamicin together. This may be because the efflux pumps are transport proteins involved in the excretion of toxic substrates from inside cells to the extracellular environment. These efflux proteins can modify the permeability of the bacterial membrane by excreting the drug, thus creating resistance to antibiotics such as Ceftazidime [46]. The study of Bialek-Davenet *et al.* [47] confirms that cephalosporins are substrates of both the *OqxAB* and the *AcrAB* efflux pumps in the bacteria *K. pneumoniae* due to their increased gene expression when detected in the bacteria *K. pneumoniae* resistant to a number of antibiotics, which is indicated by the current study.

In addition, the antibiotic Ceftazidime belongs to the group of β -lactams, so *K. pneumoniae* produces β -lactamases, which include the enzymes cephalosporinase and penicillinase. These enzymes break down the beta-lactam ring, inhibiting the action of antibiotics belonging to the penicillin and cephalosporins groups [48]. The current study is

consistent with the study of Kumar [49] in the United States, where the isolates of *K. pneumoniae* showed resistance to a number of cephalosporins, including the ceftazidime, where this resistance was attributed to the increased expression of the *OqxAB* efflux pump that includes the *oqxA* and *oqxB* genes. Rodríguez-Martínez [50] study was almost compatible with the current study for the *oqxA* gene, where the expression of this gene in the isolates of *K. pneumoniae* was 2.80 after treatment with β -lactamase antibiotics, while this same study did not correspond to the current study for the *oqxB* gene with expression of 2.82. The current study is also consistent with Razavi *et al.* [24] in Iran, where isolates treated with cephalosporins recorded high gene expression for *oqxA* and *acrAB* gene expression and moderate gene expression for *oqxB* gene. Albarri *et al.* [51] also showed resistance of *K. pneumoniae* bacteria to a number of antibiotics, including cephalosporins, and this study showed high gene expression for both the *acrAB*, *oqxA*, and *oqxB* genes in isolates resistant to cephalosporins. It also did not agree with the study of Amereh *et al.* [52]; the *oqxB* gene appeared in 2.24% of the isolates of *K. pneumoniae* treated with the cephalosporins antibiotics Chloramphenicol and Ceftriaxone.

As for the *tolC* gene, it is the outer membrane efflux protein (OEP) of bacterial cells and is associated in *K. pneumoniae* with the multi-drug efflux systems *OqxAB-TolC* and *AcrAB-TolC*. The *tolC* gene is coding separately from other efflux systems and is shared between different efflux systems and plays a crucial role in antibacterial resistance due to its function with super-family vectors (ATP-binding cassette) ABC, Resistance-nodulation-cell division (RND) and major facilitator (MF). The function of these vectors depends on the presence of OEP similar to them and does not work if their OEP does not exist. It has been observed that when mutations occur in the *tolC* gene, *K. pneumoniae* becomes highly sensitive to multiple antibiotics [53, 54]. The result of the study is consistent with several other studies that stated that the presence of the genes of *tolC*, *AcrAB*, and *mdtK* is strongly associated with multi-drug resistance patterns in *K.pneumoniae* bacteria, where these studies showed that the *AcrAB-TolC* multi-drug efflux pump system is responsible for resistance to quinolones, tetracycline, TGC, and beta-lactam antibiotics, including the Ceftazidime in many multidrug-resistant isolates [55].

The result did agree with Ferreira *et al.* [44] study conducted in Brazil on isolates of *K. pneumoniae* bacteria with multi-drug resistance to a number of antibiotics, including Ceftazidime, where the *tolc* gene recorded high gene expression of isolates. The *mdtK*, belongs to the major facilitator superfamily within the efflux pump proteins, which increases resistance to *K.pneumoniae*, as the high production of this gene leads to inactivation of carbapenems and cephalosporins [56].

The increased use of cephalosporins leads clinical isolates to increase the expression of efflux genes, including the *mdtK* gene, either by directly binding to antibiotic molecules or by promoting multiple inhibitors that inhibit the action of antibacterial agents [57]. This response can be achieved through the acquisition of genetic elements, such as plasmids or jumping genes, which enhance efflux genes or mutate the regulatory network to express efflux pumps as well as be located inside the inhibitor and change the genes of efflux pumps as in the *mdtK* gene or its regulators [58]. As for the treatment of the antibiotic Gentamicin, which belongs to the family of aminoglycosides, the *mdtK* gene recorded the highest folding (1.85 ± 0.37) in the isolates of *K. pneumoniae* bacteria, followed by the *tolC* gene with a folding of 1.10 ± 0.41 , then the *oqxA*, *oqxB*, and *acrAB* genes with folding (0.78 ± 0.35 , 0.58 ± 0.34 , 0.62 ± 0.28) respectively.

Resistance of *K.pneumoniae* isolates to aminoglycosides (Amikacine and Gentamycin) may be the result of modifications in cell permeability due to changes in *AcrAB-TolC* efflux

pump systems and due to hypothetical loss of purine KpnO. Disturbances in AcrAB-TolC may also increase bacteria's sensitivity to Gentamicin. Methyl enzymes *16SrRNA* encoded on plasmids confer resistance to all aminoglycosides. Mutations that confer resistance by modulating the target can also be a possible cause attributed to increased resistance of *K. pneumoniae* to most aminoglycosides antibiotics [59, 60]. The results of Table (6) also showed that the folding of the *mdtK* gene (4.52 ± 0.92) was the highest in treating the mixture of Ceftazidime+Gentamicin together compared to the rest of the treatments for resistant isolates. The lowest genes folding were 0.51 ± 0.24 , 0.51 ± 0.28 , 0.93 ± 0.77 and 0.96 ± 0.53 in genes *tolC*, *oqxB*, *oqxA*, and *acrAB*, respectively, in the treatment of the combination of Ceftazidime+Gentamicin antibiotics together. The use of a mixture of two antibiotics may be a promising treatment against antibiotic-resistant *K. pneumoniae* bacteria, as in the study of Shi *et al.* [61], where the antibiotic Avibactam, an antibiotic manufactured from the non- β -lactam group (Diazabicyclooctane) with the antibiotic Ceftazidime, was found that this antibiotic enhances the antibacterial activity of Ceftazidime against intestinal bacteria and some non-fermented gram-negative bacilli by inhibiting carbapenems without affecting the activity of the antibiotic Ceftazidime towards living organisms that sensitive to Ceftazidime or most anaerobic bacilli gram-negative. This is observed in the current study where most efflux genes except the *mdtK* gene were reduced on isolates of antibiotic-resistant *K.pneumoniae* that were treated with Ceftazidime+Gentamicin.

Table 6: Percentage of gene folding in antibiotic-treated resistant isolates.

Genes Treatments	Resistant isolates					p-value
	<i>oqxA</i>	<i>oqxB</i>	<i>acrAB</i>	<i>tolC</i>	<i>mdtK</i>	
Control	1.00 ± 0.00^a	0.80 ± 0.20^a	1.00 ± 0.00^a	1.00 ± 0.00^a	1.00 ± 0.00^a	
Ceftazidime	2.78 ± 1.14^a	1.00 ± 0.46^a	4.88 ± 2.73^b	1.90 ± 0.55^a	1.18 ± 0.43^a	
Gentamicin	0.78 ± 0.35^a	0.58 ± 0.34^a	0.62 ± 0.28^a	1.10 ± 0.41^a	1.85 ± 0.37^a	0.002*
Mixed	0.93 ± 0.77^a	0.51 ± 0.28^a	0.96 ± 0.53^a	0.51 ± 0.24^a	4.52 ± 0.92^b	

The different small letters indicated the presence of significant differences at $P\leq 0.05$.

The same small letters indicated non-significant differences at $P>0.05$.




Figure 4: Quantitative polymerase chain reaction curve of *16SrRNA*, *acrAB*, *TolC*, *oqxA*, *oqxB*, *mdtk* genes for resistant isolates (11, 22, 25, 33, 41).

4. Conclusion

Most *K. pneumoniae* isolates were categorized as MDR. There are highly significant differences between most of the studied treatments for gene folding in resistant isolates and the highest folding in *acrAB* gene treated with Ceftazidime antibiotic and *mdtK* gene treated with combination of antibiotics Ceftazidime+ Gentamicin. In contrast, the other genes (*oqxA*, *acrAB*, and *tolC*) were non-significant $p > 0.05$.

Ethical approval

The study protocol was approved by the College of Education for Pure Science (Ibn Al-Haitham) at the University of Baghdad and the Iraqi Ministry of Health and Environment, which numbered (39891) on 19/10/2023.

Conflict of interest

The authors declare that they have no conflicts of interest.

References

- [1] B. Tindall, G. Sutton, and G. Garrity, "*Enterobacter aerogenes* Hormaeche and Edwards 1960 (Approved Lists 1980) and *Klebsiella mobilis* Bascomb *et al.* 1971 (Approved Lists 1980) share the same nomenclatural type (ATCC 13048) on the Approved Lists and are homotypic synonyms, with consequences for the name *Klebsiella mobilis* Bascomb *et al.* 1971 (Approved Lists 1980)," *International journal of systematic and evolutionary microbiology*, vol. 67, no. 2, pp. 502-504, 2017.
- [2] L. Righini, "Analisi genomica e funzionale sui componenti del microbiota intestinale *Clostridium ramosum*, *Escherichia coli* e *Enterobacteriaceae*," 2020.
- [3] M. Pokra, D.K. Sharma, P. Mehta, H.R. Verma, S. Pundir, J. Rana, and D. Kulmi, "Its alarming, *Klebsiella* spp. towards multi-drug resistance," *International Journal of Current Microbiology and Applied Sciences*, vol. 5, no. 6, pp. 150-60, 2016.
- [4] Z.H. Aboud, A.M. Shami, and B.J. Kadhim, "Study Gene Expression of blaOXA-48 and blaVIM-1 Genes Carbapenems Resistance in *Klebsiella pneumoniae* isolated from urinary tract infections in Baghdad hospital's," *Revista Bionatura*, vol. 8, no.3, pp. 1-12, 2023.
- [5] T. M. K. K. Ghaima, "Molecular Detection of *acrAB* and *oqxAB* Genes in *Klebsiella pneumoniae* and Evaluation the Effect of Berberine on their Gene Expression," *Iraqi journal of biotechnology*, vol. 21, no. 2, 2022.
- [6] Y. Wang, R. Mowla, L. Guo, A.D. Ogunniyi, T. Rahman, M.A.D.B. Lopes, S. Ma and H. Venter, "Evaluation of a series of 2-naphthamide derivatives as inhibitors of the drug efflux pump AcrB for the reversal of antimicrobial resistance," *Bioorganic & Medicinal Chemistry Letters*, vol. 27, no. 4, pp. 733-739, 2017.
- [7] A. Al-Musawi, "Genotypic and phenotypic typing of clinical *Klebsiella pneumoniae* local isolates," M. Sc. thesis. College of Science. Mustansiriyah University, 2018.
- [8] R. A. Fodah, J.B. Scott, H.H. Tam, P. Yan, T.L. Pfeffer, R. Bundschuh, and J.M. Warawa, "Correlation of *Klebsiella pneumoniae* comparative genetic analyses with virulence profiles in a murine respiratory disease model," *PloS one*, vol. 9, no. 9, p. e107394, 2014.
- [9] H.Ziadi , F.Chougrani , A. Cheriguene , L. Carballeira , V. García and A. Mora, "Phenotypic and Genotypic Characterization of ESBL-, AmpC-, and Carbapenemase-Producing *Klebsiella pneumoniae* and High-Risk *Escherichia coli* CC131, with the First Report of ST1193 as a Causative Agent of Urinary Tract Infections in Human Patients in Algeria," *Antibiotics*, vol.14,no.5,pp.485,2025.
- [10] I. M. AL-Kadmy, H. K. Musafar, and M. H. A. A. S. Sajid, "Detection of 16S ribosomal RNA methylation in extended-spectrum β -lactamase-producing *Klebsiella pneumoniae* clinical isolates from Baghdad hospitals," *Iraqi journal of biotechnology*, vol. 14, no. 1, 2015.
- [11] K. A. Sulaiman, N. Al Qahtani, M. Al Muqrin, M. Al Dossari, A. Al Wabel, T. Al Sulaiman, R. Vishwakarma, A. Alolayan, F. Abudayah, G.B. Korayem, and O. Aljuhani, "The correlation between non-O blood group type and recurrent catheter-associated urinary tract infections in

- critically ill patients: A retrospective study," *Journal of International Medical Research*, vol. 50, no. 7, p. 03000605221108082, 2022.
- [12] I. Roca, M. Akova, F. Baquero, J. Carlet, M. Cavaleri, S. Coenen, J. Cohen, D. Findlay, I. Gyssens, O.E. Heuer, G. Kahlmeter, H. Kruse, R. Laxminarayan, E. Liébana, L. López-Cerero, A. MacGowan, M. Martins, J. Rodríguez-Baño, J.M. Rolain, C. Segovia, B. Sigauque, E. Tacconelli, E. Wellington and J. Vila, "The global threat of antimicrobial resistance: science for intervention," *New microbes and new infections*, vol. 6, pp. 22-29, 2015.
- [13] H. Venter, R. Mowla, T. Ohene-Agyei, and S. Ma, "RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition," *Frontiers in microbiology*, vol. 6, p. 377, 2015.
- [14] R. M. Martin and M. A. Bachman, "Colonization, infection, and the accessory genome of *Klebsiella pneumoniae*," *Frontiers in cellular and infection microbiology*, vol. 8, p. 4, 2018.
- [15] R.G. Elbaiomy, A.H. El-Sappah, R. Guo , X. Luo , S. Deng , M. Du , X. Jian, M. Bakeer , Z. Li, and Z. Zhang, "Antibiotic Resistance: A Genetic and Physiological Perspective," *MedComm*, vol. 6, no. e70447, 1-37, 2025
- [16] S. T. Hamad, "Prevalence of Carbapenemase Genes in *Klebsiella pneumoniae* Isolates from Patients with Urinary Tract Infections in Baghdad Hospitals," *Iraqi journal of biotechnology*, vol. 21, no. 1, 2022.
- [17] C. J. Stubenrauch, R. S. Bamert, J. Wang, and T. Lithgow, "A noncanonical chaperone interacts with drug efflux pumps during their assembly into bacterial outer membranes," *PLoS biology*, vol. 20, no. 1, p. e3001523, 2022.
- [18] G. F. Brooks, K. C. Carroll, J. S. Butel, S. A. Morse, and T. A. Mietzner, *Jawetz, Melnick, & Adelberg's medical microbiology*. Mc Graw-Hill. USA, 2013.
- [19] H. H. Al-Salhi and E. J. Al-Kalifawi, "Antimicrobial and antivirulence activity of magnesium oxide nanoparticles synthesized using *Klebsiella pneumoniae* culture filtrate," *Biochemical & Cellular Archives*, vol. 20, 2020.
- [20] K. J. Livak and T. D. Schmittgen, "Analysis of relative gene expression data using real-time quantitative PCR and the 2- $\Delta\Delta$ CT method," *methods*, vol. 25, no. 4, pp. 402-408, 2001.
- [21] H. Abbas, G. Shaker, R. Khattab, and M. Askoura, "A new role of metformin as an efflux pump inhibitor in *Klebsiella pneumoniae*," *Journal of microbiology, biotechnology and food sciences*, vol. 11, no. 1, pp. e4232-e4232, 2021.
- [22] M. Dehnamaki, M. Ghane, and L. Babaeekhou, "Detection of OqxAB and QepA efflux pumps and their association with antibiotic resistance in *Klebsiella pneumoniae* isolated from urinary tract infection," *International Journal of Infection*, vol. 7, no. 4, 2020.
- [23] F. Tayebbeh, J. Amani, S. Nazarian, M. Moradyar, and S. A. Mirhosseini, "Molecular diagnosis of clinically isolated *Klebsiella pneumoniae* strains by PCR-ELISA," *Journal of Applied Biotechnology Reports*, vol. 3, no. 4, pp. 501-505, 2016.
- [24] A. N. Mohammed, D. F. Al-Rawi, and H. K. Buniya, "Evaluation of Antibiotic Resistance of *Klebsiella Pneumoniae* Isolated from Patients in Hospitals in Iraq."
- [25] S. Razavi, R. Mirnejad, and E. Babapour, "Involvement of AcrAB and OqxAB efflux pumps in antimicrobial resistance of clinical isolates of *Klebsiella pneumoniae*," *Journal of Applied Biotechnology Reports*, vol. 7, no. 4, pp. 251-257, 2020.
- [26] N. Petrosillo, F. Taglietti, and G. Granata, "Treatment options for colistin resistant *Klebsiella pneumoniae*: present and future," *Journal of clinical medicine*, vol. 8, no. 7, p. 934, 2019.
- [27] V. Belousov , V. Strochkov , N. Sandybayev , A. Lavrinenko and M. Solomadin, "A Pilot Study of *Klebsiella pneumoniae* in Community-Acquired Pneumonia: Comparative Insights from Culture and Targeted Next-Generation Sequencing," *Diagnostics*, vol.16, no. 154, pp. 1-23,2026.
- [28] L. d. I. Maza, M. Pezzlo, J. Shigei, G. Tan, and E. Peterson, "Color atlas of medical bacteriology," 2013.
- [29] F. Omar and A. Ibrahim, "The Prevalence of Integron Class I and II Among Multi-Drug Resistance Producing *Klebsiella Pneumoniae*," *Iraqi Journal of Agricultural Sciences*, vol. 54, no. 3, pp. 619-629, 2023.
- [30] S. Qaiser, M. Zeeshan, K. Jabeen, T. Ahsan, and A. Zafar, "Comparison of chromogenic urinary tract infection medium with cysteine lactose electrolyte deficient media in a resource limited setting," *Journal of the Pakistan Medical Association*, vol. 61, no. 7, p. 632, 2011.

- [31] C. R. Mahon and D. C. Lehman, *Textbook of Diagnostic Microbiology-E-Book: Textbook of Diagnostic Microbiology-E-Book*. Elsevier Health Sciences, 2022.
- [32] B. J. Mohammed, Z. F. Saleh, J. R. Esmacel, S. F. Klaif, M. S. Jawad, and K. H. Fahad, "Identification and phylogenetic study of *Klebsiella pneumoniae* via molecular-based techniques targeting 16S rRNA, magA, and rmpA in camels from Al-Diwaniyah city, Iraq," *Annals of Tropical Medicine and Health*, vol. 23, no. 5, pp. 218-225, 2020.
- [33] W. F. Obaid and S. O. Hasson, "Pattern of Multi Drug Resistance with Biofilm Formation among *Klebsiella pneumoniae* isolated from Fecal Samples of Diarrheal Iraqi Patients," *Annals of the Romanian Society for Cell Biology*, pp. 5350-5360, 2021.
- [34] N. I. Zaidan, K. K. Ghaima, and H. M. R. Al-Haboobi, "Antibacterial Activity of Antimicrobial Peptide Indolicidin against Multidrug-Resistant *Klebsiella pneumoniae* Isolated from Patients with Burns," *Indian Journal of Forensic Medicine & Toxicology*, vol. 16, no. 2, pp. 282-290, 2022.
- [35] N. Perween, S. K. Prakash, and O. Siddiqui, "Multi drug resistant *Klebsiella* isolates in burn patients: a comparative study," *Journal of clinical and diagnostic research: JCDR*, vol. 9, no. 9, p. DC14, 2015.
- [36] F. S. Codjoe, *Detection and characterisation of carbapenem-resistant gram-negative bacilli infections in Ghana*. Sheffield Hallam University (United Kingdom), 2016.
- [37] R. Tan, A. Yu, Z. Liu, Z. Liu, R. Jiang, X. Wang, J. Liu, J. Gao, and X. Wang, "Prediction of minimal inhibitory concentration of meropenem against *Klebsiella pneumoniae* using metagenomic data," *Frontiers in Microbiology*, vol. 12, p. 712886, 2021.
- [38] C. a. I. s. i. (CLSI), "M 100 performance standards for antimicrobial susceptibility testing ", 2020, vol. 30th.
- [39] N. Narimisa, F. Amraei, B. S. Kalani, R. Mohammadzadeh, and F. M. Jazi, "Effects of sub-inhibitory concentrations of antibiotics and oxidative stress on the expression of type II toxin-antitoxin system genes in *Klebsiella pneumoniae*," *Journal of global antimicrobial resistance*, vol. 21, pp. 51-56, 2020.
- [40] D. I. Andersson and D. Hughes, "Microbiological effects of sublethal levels of antibiotics," *Nature Reviews Microbiology*, vol. 12, no. 7, pp. 465-478, 2014.
- [41] A. A. Mahdi and R. M. Abdullah, "Molecular study of Carbapenime resistant genes in *Acinetobacter baumannii* that isolated from different clinical cases," *Biochemical and Cellular Archives*, vol. 20, no. 1, pp. 1605-10, 2020.
- [42] D. M. Jacobs, M. C. Safir, D. Huang, F. Minhaj, A. Parker, and G. G. Rao, "Triple combination antibiotic therapy for carbapenemase-producing *Klebsiella pneumoniae*: a systematic review," *Annals of clinical microbiology and antimicrobials*, vol. 16, pp. 1-12, 2017.
- [43] M. S. Mulani, E. E. Kamble, S. N. Kumkar, M. S. Tawre, and K. R. Pardesi, "Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review," *Frontiers in microbiology*, vol. 10, p. 539, 2019.
- [44] R. L. Ferreira, B.C.M. da Silva, G.S. Rezende, R. Nakamura-Silva, A. Pitondo-Silva, E.B. Campanini, M.C.A. Brito, E.M.L. da Silva, C.C.M. Freire, A.F. da Cunha and M.D.S. Pranchevicius, "High prevalence of multidrug-resistant *Klebsiella pneumoniae* harboring several virulence and β -lactamase encoding genes in a Brazilian intensive care unit," *Frontiers in microbiology*, vol. 9, p. 3198, 2019.
- [45] Y. Li, S. Kumar, L. Zhang, H. Wu, and H. Wu, "Characteristics of antibiotic resistance mechanisms and genes of *Klebsiella pneumoniae*," *Open Medicine*, vol. 18, no. 1, p. 20230707, 2023.
- [46] M. Heidary, A. Bahramian, A. Hashemi, M. Goudarzi, V.F. Omrani, G. Eslami, and H. Goudarzi, "Detection of *acrA*, *acrB*, *aac* (6')-Ib-cr, and *qepA* genes among clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae*," *Acta microbiologica et immunologica Hungarica*, vol. 64, no. 1, pp. 63-69, 2017.
- [47] S. Bialek-Davenet, J.P. Lavigne, K. Guyot, N. Mayer, R. Tournebize, S. Brisse, V. Leflon-Guibout, and M.H. Nicolas-Chanoine, "Differential contribution of *AcrAB* and *OqxAB* efflux pumps to multi-drug resistance and virulence in *Klebsiella pneumoniae*," *Journal of Antimicrobial Chemotherapy*, vol. 70, no. 1, pp. 81-88, 2015.

- [48] A. Abdu, M. Kachallah, and D. Y. Bolus, "Antibiotic susceptibility patterns of Uropathogenic *Escherichia coli* among patients with urinary tract infections in a tertiary care hospital in Maiduguri, North Eastern, Nigeria," *Journal of Bioscience and Biotechnology Discovery*, vol. 3, pp. 14-24, 2018.
- [49] A. R. Kumar, "Antimicrobial sensitivity pattern of *Klebsiella pneumoniae* isolated from sputum from tertiary care hospital, Surendranagar, Gujarat and issues related to the rational selection of antimicrobials," *Scholars Journal of Applied Medical Sciences*, vol. 1, no. 6, pp. 928-933, 2013.
- [50] J. M. Rodríguez-Martínez, P. Díaz de Alba, A. Briales, J. Machuca, M. Lossa, F. Fernández-Cuenca, J. Rodríguez Baño, L. Martínez-Martínez, and A. Pascual, "Contribution of OqxAB efflux pumps to quinolone resistance in extended-spectrum- β -lactamase-producing *Klebsiella pneumoniae*," *Journal of Antimicrobial Chemotherapy*, vol. 68, no. 1, pp. 68-73, 2013.
- [51] O. Albarri, M. AlMatar, I. Var, and F. Köksal, "Antimicrobial Resistance of Clinical *Klebsiella pneumoniae* Isolates: Involvement of AcrAB and OqxAB Efflux Pumps," *Current molecular pharmacology*, vol. 17, no. 1, p. e310323215266, 2024.
- [52] F. Amereh, M. R. Arabestani, and L. Shokoohizadeh, "Relationship of OqxAB efflux pump to antibiotic resistance, mainly fluoroquinolones in *Klebsiella pneumoniae*, isolated from hospitalized patients," *Iranian Journal of Basic Medical Sciences*, vol. 26, no. 1, p. 93, 2023.
- [53] X. R. Bina, Y. Weng, J. Budnick, M. E. Van Allen, and J. E. Bina, "*Klebsiella pneumoniae* TolC contributes to antimicrobial resistance, exopolysaccharide production, and virulence," *Infection and Immunity*, vol. 91, no. 12, pp. e00303-23, 2023.
- [54] L. He, W. Wang, L. Ma, D. Wang, and S. Long, "Emergence of a clinical *Klebsiella pneumoniae* harboring an acrAB-tolC in chromosome and carrying the two repetitive tandem core structures for bla KPC-2 and bla CTX-M-65 in a plasmid," *Frontiers in Cellular and Infection Microbiology*, vol. 14, p. 1410921, 2024.
- [55] R. Lagha Ben, F. Abdallah, A.A.H. ALKhamash, N. Amor, M.M. Hassan, I. Mabrouk, M. Alhomrani, and A. Gaber, "Molecular characterization of multi-drug resistant *Klebsiella pneumoniae* clinical isolates recovered from King Abdulaziz Specialist Hospital at Taif City, Saudi Arabia," *Journal of Infection and Public Health*, vol. 14, no. 1, pp. 143-151, 2021.
- [56] E. Gato, J.C. Vázquez-Ucha, S. Rumbo-Feal, L. Álvarez-Fraga, J.A. Vallejo, M. Martínez-Gutián, A. Beceiro, J. Ramos Vivas, P.J. Sola Campoy, M. Pérez-Vázquez, J. Oteo Iglesias, B.K. Rodiño-Janeiro, A. Romero, M. Poza, G. Bou and A. Pérez, "Kpi, a chaperone-usher pili system associated with the worldwide-disseminated high-risk clone *Klebsiella pneumoniae* ST-15," *Proceedings of the National Academy of Sciences*, vol. 117, no. 29, pp. 17249-17259, 2020.
- [57] E.A. Muhsin, S.S. Al-Jubori and L.A. Said, "Prevalence of Efflux Pump and Porin-Related Antimicrobial Resistance in Clinical *Klebsiella pneumoniae* in Baghdad, Iraq," *Archives of Razi Institute*, Vol. 77, no. 2, pp. 785-798, 2022.
- [58] L. Joseph, T. Merciecca, C. Forestier, D. Balestrino, and S. Miquel, "From *Klebsiella pneumoniae* colonization to dissemination: an overview of studies implementing murine models," *Microorganisms*, vol. 9, no. 6, p. 1282, 2021.
- [59] C. Y. Effah, T. Sun, S. Liu, and Y. Wu, "*Klebsiella pneumoniae*: an increasing threat to public health," *Annals of clinical microbiology and antimicrobials*, vol. 19, pp. 1-9, 2020.
- [60] T. X. N. Huy, "Overcoming *Klebsiella pneumoniae* antibiotic resistance: new insights into mechanisms and drug discovery," *Beni-Suef University Journal of Basic and Applied Sciences*, vol. 13, no. 1, p. 13, 2024.
- [61] Y. Shi, J. Hu, P. Liu, T. Wang, H. Wang, Y. Liu, O. Cao, and X. Zuo, "Ceftazidime–avibactam-based versus tigecycline-based regimen for the treatment of carbapenem-resistant *Klebsiella pneumoniae*-induced pneumonia in critically ill patients," *Infectious diseases and therapy*, vol. 10, pp. 2721-2734, 2021.